Vertex Pharmaceuticals (BSP:VRTX34) Tariff Resilience Score: 7/10 (As of Jul. 04, 2026)


BSP:VRTX34 Vertex Pharmaceuticals Inc BSP:VRTX34
85 GF Score
Price R$690.50
GF Value R$658.53
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Tariff Resilience Score?

Vertex Pharmaceuticals BSP:VRTX34 +1.86% 85 Tariff Resilience Score is 7 as of Jul. 04, 2026. GuruFocus rates BSP:VRTX34 with a GF Score™ of 85/100 and a GF Value™ of R$658.53 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,373 Biotechnology companies, Vertex Pharmaceuticals ranks better than 90.39% on this metric.

Vertex Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Vertex Pharmaceuticals has Vertex's pharmaceutical focus limits tariff exposure, though it relies on global supply chains for raw materials. Manufacturing is primarily in the US, with international sales. Historical impacts are minimal, and the company can leverage pricing power and alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Vertex Pharmaceuticals might have Highly Resilient.

Vertex Pharmaceuticals  (BSP:VRTX34) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Vertex Pharmaceuticals Tariff Resilience Score Related Terms

BSP:VRTX34 vs REGN, ALNY, RVMD: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vertex Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Tariff Resilience Score falls into.


BSP:VRTX34
85GF Score
Vertex Pharmaceuticals Inc BSP:VRTX34
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Vertex Pharmaceuticals (BSP:VRTX34) has a Tariff Resilience Score of 7 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Vertex Pharmaceuticals ranks #132 out of 1373 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Vertex Pharmaceuticals' Tariff Resilience Score too high?
Vertex Pharmaceuticals' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Vertex Pharmaceuticals' value of 7 is 75% above this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #132 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Tariff Resilience Score compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #132 out of 1373 companies for Tariff Resilience Score. This places Vertex Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Vertex Pharmaceuticals' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (BSP:VRTX34) is currently considered Fairly Valued. The stock's GF Value™ is R$658.53, compared to a current price of R$690.50 — trading 4.9% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Vertex Pharmaceuticals' overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Vertex Pharmaceuticals (BSP:VRTX34), the current Tariff Resilience Score is 7 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (BSP:VRTX34) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued. The current stock price of R$690.50 is trading 4.9% above its estimated GF Value™ of R$658.53. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for BSP:VRTX34:

  • Tariff Resilience Score: 7
  • GF Value™: R$658.53 vs. price of R$690.50 (4.9% above fair value)
  • GF Score™: 85/100 with 6 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1373)

No single metric tells the full story. See the BSP:VRTX34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
85GF Score

Get the complete analysis for BSP:VRTX34

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$690.50
Price
R$658.53
GF Value